TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65 years.~* 8/8 or 7/8 HLA-identical matched sibling OR Allele level 8/8 (HLA-A, B, C, DR Beta1)matched unrelated donor or 4/6 or better HLA matched cord blood.~* Patients with high risk hematologic malignancies who are appropriate candidates for a myeloablative allogeneic stem cell transplantation.~* Patients with a history of CNS disease must have been treated and have no active CNS disease at the time of protocol treatment.~* ECOG performance status \< or equal to 2~* Patients must have adequate function of other organ systems as measured by:~* Creatinine clearance (by Cockcroft Gault equation) \> or equal to 30ml/min. Hepatic transaminases (ALT/AST) \< or equal to 4 x normal, bilirubin \< or equal to 2.0 mg/dl.~* Pulmonary function tests demonstrating FVC and FEV1 of \> or equal to 50% of predicted for age and DLCO \> or equal to 50% of predicted.~* Ejection fraction of \> or equal to 45% by echocardiogram, radionuclide scan or cardiac MRI.~* Patients must be HIV negative.~* Patients must not be pregnant.~Exclusion Criteria:~* Patients with \> 5% blasts in bone marrow or peripheral circulation.~* Uncontrolled infection.~* Class III or IV angina as per NYHA criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transplant Recipients (Type: EXPERIMENTAL): Transplant recipients from matched sibling donors and dual cord donors. Subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed MS according to the IDF criteria:~* - - Waist circumference: ≥80 cm (women) ≥90 cm (men), plus two or more of the following:~* - - - - Fasting glucose ≥ 100 mg/dL~* - - - - Triglycerides ≥150 mg/dL~* - - - - HDL-C: Men ≤40 mg/dL, women ≤50 mg/dL~* - - - - Blood pressure ≥130/85 mmHg~* Body Mass Index between 25 and 34.9 kg/m²~* No pharmacological treatment for MS~* Stable weight during the last 3 months~Exclusion Criteria:~* Pregnancy or breast-feeding~* History of kidney or liver disease~* Drugs or supplements consumption with proven properties that modify the behavior of the MS~* Total cholesterol \>240 mg/dL~* Triglycerides \>500mg/dL~* Glucose ≥126 mg/dL or HbA1C ≥6.5%.~* Hypersensitivity to Fucoxanthin

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Fucoxanthin (Type: EXPERIMENTAL): 12 mg Fucoxanthin capsule, once a day before breakfast during 90 days.
- Placebo (Type: PLACEBO_COMPARATOR): Homologated magnesium sterate capsule, once a day before breakfast during 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV negative as determined by concordant rapid testing~* HSV-2 seropositive (Focus HerpeSelect \>3.4)~* At least one prior occurrence of GUD~* 18-50 years of age~Exclusion Criteria:~* Current use, or use w/in past 7 days of acyclovir, valacyclovir, or famciclovir~* Prior hypersensitivity \&/or allergic reaction to acyclovir~* Use of probenicid~* Current use, or use within past 28 days, of an investigational agent~* Currently pregnant or nursing~* Currently plan to become pregnant during next 3 months~* Any condition that will interfere with successful completion of study procedures

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- acyclovir (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Convenience Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Cohort A:~1. A. Written informed consent prior to participation~2. A. Female and male patients \>= 18 years of age with a diagnosis of non-valvular atrial fibrillation.~3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.~4. A. Patients switched to Pradaxa® according Summary of Product Characteristics and physician's discretion.~OR~Cohort B:~1. B. Written informed consent prior to participation.~2. B. Female and male patients \>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (OAC) within one year prior to enrolment).~3. B. Stroke prevention treatment initiated with Pradaxa® or VKA according to Summary of Product Characteristics and physician's discretion.~Exclusion criteria:~1. Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC).~2. Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in atrial fibrillation.~3. Current participation in any clinical trial of a drug or device.~4. Current participation in an European registry on the use of oral anticoagulation in AF.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switch patients / A (Type: None): Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
- New AF patients / B (Type: None): Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a New Technique -IN-REC-SUR-E- in Preterm Neonates With RDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. In-Born at 24+0-27+6 (and)~2. Spontaneously breathing at birth but requiring respiratory support (CPAP or O2) at 5' of life (and)~3. Parental consent has been obtained (and)~4. Failing nCPAP during the first 24 hours of life~Exclusion Criteria:~1. Severe birth asphyxia or a 5-minute Apgar score \<3~2. Endotracheal intubation in the delivery room for resuscitation or insufficient respiratory drive according to AAP guidelines16~3. Prolonged PROM \> 3 weeks~4. Presence of major congenital malformations~5. Hydrops fetalis~6. Inherited disorders of metabolism

- Gender: ALL
- Minimum Age: 24 Weeks
- Maximum Age: 27 Weeks
- Healthy Volunteers: f

Study Arms:
- INRECSURE (Type: EXPERIMENTAL): Infants in the INRECSURE arm will undergo the following approach: as soon as possible after the recruitment manoeuver (at CDP-Optimal) a dose of poractant alfa (Curosurf \[Chiesi Farmaceutici, Parma, Italy\]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. A temporary reduction of frequency may be necessary to increase the VT up to 2.5 ml/kg for improving the surfactant spreading.
- INSURE (Type: ACTIVE_COMPARATOR): Infants in the INSURE arm will undergo the following approach: after intubation, a dose of poractant alfa (Curosurf \[Chiesi Farmaceutici, Parma, Italy\]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. During surfactant administration, infants will be manually ventilated to facilitate surfactant distribution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent~* Clinically normal physical findings and laboratory values as judged by the investigator including negative test of Hepatitis B surface antigen, antibodies to HIV virus and antibodies to hepatitis C virus.~Exclusion Criteria:~* Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the Investigational Product~* History of psychiatric or somatic disease/condition that may interfere with the objectives of the study, as judged by the investigator

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 8 increasing oral single doses given to 8 groups (3 on active and 1 on placebo in each group)
- 2 (Type: EXPERIMENTAL): 2 oral doses of AZD1656 given to 2 groups together with food

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Propolis as Adjuvant in the Healing of Human Diabetic Foot Wounds

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DM type 1 or 2 with complicated foot diabetics wounds.~* 18-80 years old~Exclusion Criteria:~* Propolis allergy~* Critical ischemia~* Severe infection~* Psycho-social conditions that avoid regular attendance at health aid.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propolis group (Type: None): The patients receive propolis (3% in Propylene Glycol) in all the wound surface in each healing until cicatrisation or at least 8 weeks. (n=20)
- control group (Type: None): the patients received the same care in the healing of their wounds, but no new component or propolis 3% was administered (n=8)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Vibration System on Pain Reduction During Injection of Local Dental Anaesthesia in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children 5-12 years of age.~2. Positive or definitely positive behavior on Frankl scale.6~3. Children receiving treatment on the dental chair.~4. Free from allergies to topical anesthetic used in the study.~5. Parental consent for child participation in the study.~Exclusion Criteria:~1. Those in need of treatment under general anesthesia will be excluded from the study.~2. Children with allergies from topical anesthesia

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Buzzy (Type: EXPERIMENTAL): Buzzy was used during Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel.
- Control (Type: ACTIVE_COMPARATOR): Maxillary anesthetic infiltration injection with 2%lidocaine with 1:50,000 epinephrine after topical application with 20% Benzocaine topical gel only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Light Emitting Diode (LED) for the Treatment of Wrinkles

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subjects with aged/photodamaged skin~Exclusion Criteria:~* Subjects were not allowed to participate in this study if they were taking cortisone (Prednisone), anticoagulant therapy, or any drug known to increase photosensitivity. In addition, during the 12 months preceding the study, subjects were required not to have used isotretinoin (Accutane), or applied topical steroids to the site to be treated. Moreover, previous laser or topical medication at the to-be-treated site was not permitted.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sham light (Type: SHAM_COMPARATOR): one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with a Sham light on the experimental periorbital area
- LED-treated (Type: EXPERIMENTAL): one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with 660 nm Light emitting diode (LED) on the experimental periorbital area

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose of pGM169/GL67A in CF Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cystic fibrosis confirmed by sweat testing or genetic analysis~* Males and females aged 16 years and above~* Forced expiratory volume in the 1st second (FEV1) \> 60% predicted values~* Clinical stability at entry~* Prepared to take effective contraceptive precautions for the duration of their participation in the study and for 3 months thereafter~* If taking regular rhDNase (pulmozyme) is willing, and considered able by independent medical carers, to withhold treatment for 24 hours before and 24 hours after the gene therapy dose~* Written informed consent obtained~* Permission to inform GP of participation in study~Exclusion Criteria:~* Infection with Burkholderia cepacia complex organisms or MRSA~* Significant nasal pathology including polyps, clinically-significant rhinosinusitis, or recurrent severe epistaxis (nose bleeds)~* Acute upper respiratory tract infection within the last 2 weeks~* Previous spontaneous pneumothorax without pleurodesis~* Recurrent severe haemoptysis~* Current smoker~* Significant comorbidity including:~  1. Moderate/severe CF liver disease~ 2. Significant renal impairment~ 3. Significant coagulopathy~* Receiving 2nd line immunosuppressant drugs such as methotrexate, cyclosporine, intravenous immunoglobulin preparations~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 20ml pGM169/GL67A (Type: EXPERIMENTAL): Received a nebulized dose 20ml via an breath-actuated nebulizer
- 10ml pGM169/GL67A (Type: EXPERIMENTAL): Received a nebulized dose 10ml via an breath-actuated nebulizer
- 5ml pGM169/GL67A (Type: EXPERIMENTAL): Received a nebulized dose 5ml via an breath-actuated nebulizer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 8-21 years~* Diagnosis of Crohn disease \> 6 months~* Tibia vBMD z-score \< 25th%tile for age and sex~Exclusion Criteria:~* Pregnancy~* Weight \> 250 lb~* Medical illness (unrelated to Crohn)~* Cognitive/developmental disorder~* Do not speak English~* \> 1 primary residence~* Unwilling to commit to 2 year study~* Sibling or cousin enrolled in trial

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Active Low Magnitude Mechanical Stimulus (Type: ACTIVE_COMPARATOR): Active Low Magnitude Mechanical Stimulus
- Inactive Low Magnitude mechanical Stimulus (Type: PLACEBO_COMPARATOR): Inactive, or placebo low magnitude mechanical stimulus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physiologic Growth Hormone Effects in HIV Lipodystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women age 18-60~* Previously diagnosed HIV infection~* Stable antiviral regimen for at least 12 weeks prior to enrollment~* Waist-to-hip ratio \>0.90 for men and \>0.85 for women~* Evidence of at least one of the following recent changes: \*increased abdominal girth,~  \*relative loss of fat in the extremities, \*relative loss of fat in the face~* Simulated peak GH response to arginine/GHRH of less than 7.5 mcg/dL~Exclusion Criteria:~* Use of Megace, anti-diabetic agents, GH, or other anabolic agents, pharmacologic glucocorticoid (prednisone \>5 mg/day or its equivalent) for 3 months prior to enrollment. Patients on a standard dose of testosterone for documented hypogonadism will be allowed to enter the protocol. Women taking standard estrogen replacement therapy for \>3 months will be allowed in the study.~* Diabetes mellitus~* Other severe chronic illness~* HgB \<9.0 g/dL, creatinine \>1.4 mg/dL, or PSA \>4 ng/mL~* Positive BHCG or failure to use appropriate birth control during study. Acceptable methods include oral contraceptives, depo provera or combined progesterone-estrogen injections, transdermal contraceptive patches, IUD's, barrier devices (condoms, diaphragms), and abstinence.~* Carpal tunnel syndrome~* Active malignancy or history of pituitary malignancy, history of colon cancer or prostate malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): recombinant human growth hormone subcutaneously once a day
- 2 (Type: PLACEBO_COMPARATOR): placebo subcutaneously once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is ≥ 18 years of age;~* Voluntarily signed informed consent;~* Patient is male, or female with negative pregnancy test prior to enrolment;~* Patient has a proven HIV-1 infection (with positive antibodies against HIV-1 and a detectable plasma HIV-1 RNA);~* Patient must be on stable treatment with HAART for at least 6 months (HAART is defined as an antiretroviral regimen consisting of at least three registered antiretroviral agents\*);~* Mean of all measured CD4+ cell counts during the 6 months prior to the start of HAART must be above or equal to 200 cells/ mm3~* Current CD4+ cell count must be at least 450 cells/ mm3;~* HIV-RNA must be below 50 copies/ mL for the last 6 months prior to inclusion, during at least two measurements (occasional so called 'blips' up to 50 copies/mL are permitted);~* Patient is one of the following: not sexually active, or a heterosexually active female, agreeing to use condoms with her partner from 14 days prior to the first vaccination until 4 months after the last, even though using another method of contraception, and willing to undergo pregnancy tests during screening and prior to each vaccination, or a male, agreeing to use condoms with his partner from the day of the first vaccination until 4 months after the last vaccination.~Exclusion Criteria:~* Treatment with a non-HAART regimen of antiretroviral agents prior to the start of HAART;~* History of a CDC class C event (see Appendix);~* Interruption of HAART during the course of the study which is expected at the time of inclusion;~* History of exposure \<20 years ago to any poxvirus based vaccine;~* Patient is female and has a positive pregnancy test or the wish of pregnancy:~* Active opportunistic infection, or any active infection or malignancy within 30 days prior to screening visit;~* Therapy with immunomodulatory agents, including cytokines (e.g. IL2) and gamma globulin, or cytostatic chemotherapy within 90 days prior to screening visit;~* History of allergy to any vaccine component;~* Use of anti-coagulant medication;~* Use of any investigational drug during the 90 days prior to study entry;~* Previous failure to antiretroviral and/or mutations conferring genotypic resistance to antiretroviral therapy~* Any other condition which, in the opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine group (Type: EXPERIMENTAL): Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete